Stock VXL VAXIL BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vaxil Bio Ltd.

Equities

VXL

CA92243L1076

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 08:55:43 08/05/2024 pm IST 		5-day change 1st Jan Change
0.01 CAD 0.00% Intraday chart for Vaxil Bio Ltd. 0.00% -60.00%
30/04 Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04/03 Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. in a reverse merger transaction. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2.668 3.113 34.74 10.27 2.74 3.424
Enterprise Value (EV) 1 1.964 3.148 33.24 8.032 1.23 2.486
P/E ratio -2.44 x -2.7 x -22.5 x -10.4 x -4.69 x -13.5 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -1.99 x -2.85 x -24.8 x -8.31 x -2.11 x -9.87 x
EV / FCF -2.26 x -18.8 x -55 x -11.4 x -2.39 x -5.34 x
FCF Yield -44.2% -5.31% -1.82% -8.74% -41.9% -18.7%
Price to Book 6.13 x -5.34 x 44.3 x 6.04 x 2.41 x 3.84 x
Nbr of stocks (in thousands) 88,929 88,929 1,15,809 1,36,979 1,36,979 1,36,979
Reference price 2 0.0300 0.0350 0.3000 0.0750 0.0200 0.0250
Announcement Date 23/04/19 27/04/20 29/04/21 29/04/22 27/04/23 29/04/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -0.985 -1.106 -1.343 -0.967 -0.582 -0.252
EBIT 1 -1.041 -1.143 -1.347 -0.986 -0.584 -0.254
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.047 -1.154 -1.358 -0.986 -0.584 -0.254
Net income 1 -1.047 -1.154 -1.358 -0.986 -0.584 -0.254
Net margin - - - - - -
EPS 2 -0.0123 -0.0130 -0.0133 -0.007244 -0.004263 -0.001854
Free Cash Flow 1 -0.8684 -0.1672 -0.6048 -0.7022 -0.515 -0.4658
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 23/04/19 27/04/20 29/04/21 29/04/22 27/04/23 29/04/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 0.04 - - - -
Net Cash position 1 0.7 - 1.5 2.24 1.51 0.94
Leverage (Debt/EBITDA) - -0.0316 x - - - -
Free Cash Flow 1 -0.87 -0.17 -0.6 -0.7 -0.52 -0.47
ROE (net income / shareholders' equity) 4,027% 1,559% -1,229% -78.8% -41.2% -25.1%
ROA (Net income/ Total Assets) -108% -130% -90.2% -31.2% -19.1% -12.6%
Assets 1 0.9655 0.8844 1.505 3.157 3.061 2.014
Book Value Per Share 2 0 -0.0100 0.0100 0.0100 0.0100 0.0100
Cash Flow per Share 2 0.0100 0 0.0100 0.0200 0.0100 0.0100
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 23/04/19 27/04/20 29/04/21 29/04/22 27/04/23 29/04/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VAXIL BIO LTD. Stock Vaxil Bio Ltd.
-60.00% 998K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 108B
ARGENX SE Stock argenx SE
+7.02% 23.46B
BIONTECH SE Stock BioNTech SE
-14.60% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.53B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.81B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VXL Stock
  4. Financials Vaxil Bio Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW